Companies Dominating the Osteoarthritis Gene Therapy Landscape
- Sanofi-aventis Groupe
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Horizon Therapeutics plc
- Hanmi Pharm. Co., Ltd.
- ALMATICA PHARMA LLC.
- Assertio Holdings, Inc.
- Flexion Therapeutic, Inc.
- Zimmer Biomet Holdings, Inc.
- Pfizer Inc.
- Virchow Biotech Privet Limited
- Bayer AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of osteoarthritis gene therapy is estimated at USD 8.61 billion.
Osteoarthritis Gene Therapy Market size was valued at USD 8.07 billion in 2024 and is likely to cross USD 21.68 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037.
Europe industry is estimated to dominate majority revenue share by 2037, on the back of increasing geriatric population with osteoarthritis disease.
The major players in the market are Sanofi-aventis Groupe, Horizon Therapeutics plc, Hanmi Pharm. Co., Ltd., ALMATICA PHARMA LLC., Assertio Holdings, Inc., Flexion Therapeutic, Inc., Zimmer Biomet Holdings, Inc., Pfizer Inc., and others.
